3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
9
Leukemia, Myeloid, Acute
3
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Interventions
Cytarabine
22
Mitoxantrone
7
Etoposide
7
Idarubicin
6
tipifarnib
4
Filgrastim
4
Topotecan
3
Sorafenib
3
Lenalidomide
3
Daunorubicin
3
Cyclophosphamide
3
Clofarabine
3
Bortezomib
3
Azacitidine
3
veliparib
2
tanespimycin
2
fludarabine phosphate
2
alvocidib
2
Imatinib Mesylate
2
Everolimus
2
Carboplatin
2
Arsenic Trioxide
2
trebananib
1
romidepsin
1
perifosine
1
octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate
1
ispinesib
1
entinostat
1
eltrombopag
1
choline magnesium trisalicylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Leukemia, Myelomonocytic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn